Lupin Launches Azilsartan Medoxomil Tablets in the United States

Global pharma major Lupin Limited (Lupin) today announced the launch of Azilsartan Medoxomil Tablets, 40mg and 80mg in the United States following the approval from the U.S. FDA for its Abbreviated New Drug Application. The product is bioequivalent to Edarbi® of Azurity Pharmaceuticals, Inc. and indicated for the treatment of hypertension in adults to lower blood pressure. Lupin is the exclusive first-to-file for this product and is eligible for 180-day generic drug exclusivity.

Azilsartan Medoxomil Tablets (RLD Edarbi®) had estimated annual sales of USD 53.5 million in the U.S. (IQVIA MAT APRIL 2026)

Shares of Lupin Limited was last trading in BSE at Rs. 2266.80 as compared to the previous close of Rs. 2277.00. The total number of shares traded during the day was 44751 in over 2606 trades.

The stock hit an intraday high of Rs. 2283.60 and intraday low of 2253.90. The net turnover during the day was Rs. 101428891.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Pharmaceuticals AzilsartanMedoxomil Tablets USA